Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives

Esophageal cancer is the sixth most common cause of cancer-related mortality worldwide. The standard treatment for unresectable esophageal cancer is systemic chemotherapy. However, the survival benefit is limited, with a median overall survival of less than 10 months. The advent of immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagata, Yusuke, Yamamoto, Shun, Kato, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Immunotherapeutics – Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746438/
https://www.ncbi.nlm.nih.gov/pubmed/36375821
http://dx.doi.org/10.1080/21645515.2022.2143177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746438/
https://www.ncbi.nlm.nih.gov/pubmed/36375821
http://dx.doi.org/10.1080/21645515.2022.2143177

Ejemplares similares